MDA's Power of Collaboration in Shaping Advocacy and Policy for Neuromuscular Diseases: Paul Melmeyer, MPP
Ahead of the 2024 MDA Conference, the vice president of public policy and advocacy at the Muscular Dystrophy Association talked about conference advocacy collaboration, access to treatments, and the state of healthcare. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
"What the conference also allows us to do is convene with the clinicians—those who are diagnosing individuals with neuromuscular diseases and prescribing new treatments. Oftentimes, we engage with them during sessions with our care center directors or those focused on gene therapies, both within the conference sessions and beyond."
On March 3rd, 2024, the
Addressing these challenges may be completed through health policy, a realm well-versed by
Recently, NeurologyLive® sat down with Melmeyer to explain how the neuromuscular advocacy collaborative leverages collective voices to drive effective public policymaking for those with neuromuscular conditions. In an era in which FDA approvals for neuromuscular disease are at an all-time high, he talked about some specific access challenges that are hindering the community, and how the MDA is addressing these issues. Additionally, Melmeyer spoke about how the MDA Conference serves as a catalyst for cross-stakeholder collaboration, influencing initiatives and policy changes in the neuromuscular disease community.
Registration for the 2024 MDA Conference is now open! The meeting is set to be held at the Hilton Orlando, in Orlando, Florida, from March 3 to 6, 2024. To register and for more information, head to
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025